Dutch biotech SME engineering oxidoreductases and lignin-degrading enzymes for circular consumer products and biorefinery applications.
GECCO BIOTECH is a Dutch biotech SME based in Groningen that engineers enzymes — primarily oxidoreductases and lignin-degrading bacterial enzymes — for industrial and consumer applications. Their core capability is protein engineering: taking enzymes found in nature, understanding their structure-function relationships, and redesigning them through directed evolution and computational methods to perform better in real-world processes. They apply this expertise across two distinct but related domains: breaking down lignin and lignocellulose for biorefinery applications, and developing oxidative enzymes for circular consumer products such as detergents, cosmetics, textiles, and nutraceuticals. As an SME, they serve as the industrial bridge in academic-led consortia, translating fundamental enzyme science into application-ready biocatalysts.
Both B-LigZymes and OXIPRO explicitly involve engineering enzyme function — B-LigZymes through structure-function analysis of bacterial lignin enzymes, OXIPRO through an oxidoreductase foundry approach combining in silico design with experimental iteration.
B-LigZymes (2019–2024) focused specifically on bacterial enzymes and bioprocesses for lignin valorization, including bioaromatics production and green chemistry from lignocellulosic feedstocks.
OXIPRO (2021–2025, EUR 295,508) is centered on building an oxidoreductase foundry to supply circular, environment-friendly enzymes for textiles, detergents, cosmetics, and nutraceuticals.
OXIPRO introduced in silico methods and supercomputing into GECCO BIOTECH's toolkit, signaling a move toward computationally-guided enzyme engineering alongside wet-lab directed evolution.
OXIPRO's keyword set includes RRI, consumer-oriented, industry-driven, and science with and for society — indicating GECCO BIOTECH contributes to stakeholder engagement and co-creation frameworks within the project, not just technical work.
In their first H2020 project (B-LigZymes, 2019), GECCO BIOTECH was squarely focused on fundamental enzyme biochemistry applied to a specific industrial challenge — breaking down lignin using bacterial enzymes, with emphasis on understanding structure-function relationships and developing biorefinery-relevant bioprocesses. By their second project (OXIPRO, 2021), the focus shifted meaningfully: the feedstock-processing angle gave way to a consumer product orientation, with oxidoreductases targeted at textiles, detergents, cosmetics, and nutraceuticals rather than biomass deconstruction. A second notable shift is methodological — OXIPRO brings computational design (in silico, supercomputing) alongside traditional directed evolution, suggesting the company is building a more industrialized, platform-style enzyme development capability rather than project-by-project custom work.
GECCO BIOTECH is moving from niche biorefinery enzyme work toward a broader industrial enzyme platform play, combining computational design with circular economy positioning — making them an increasingly attractive partner for consumer goods companies seeking biocatalytic alternatives to chemical processes.
GECCO BIOTECH has participated exclusively as a consortium partner — never as coordinator — across both projects, which is consistent with their profile as a specialist SME that brings focused enzymatic expertise to larger research programs. Despite only two projects, they have accumulated 24 unique consortium partners across 14 countries, indicating that each consortium was substantial in size and geographic breadth; this is not a company that works in small, tight-knit teams. They appear to operate as a reliable specialist node: brought in for their enzyme engineering know-how while academic partners handle fundamental research and other industry partners handle scale-up or market development.
With 24 unique partners across 14 countries from just two projects, GECCO BIOTECH sits inside large, genuinely European consortia — averaging roughly 12 partners per project. Their geographic reach spans most of the EU's major research nations, though the Netherlands hub and Groningen's strong biotech ecosystem likely anchor their most active relationships.
GECCO BIOTECH occupies a rare niche: an SME that operates at the intersection of academic protein science and industrial enzyme application, without being either a university spin-out still in research mode or a large enzyme company (like Novozymes or DSM) that dominates commercial markets. Their combination of directed evolution, structural biochemistry, and growing computational design capability — applied across both biorefinery and consumer product contexts — means they can serve as the translational engine in consortia that need to move from enzyme discovery to application-ready biocatalysts. For a consortium coordinator looking for an industry partner who won't just tick the SME box but will actively contribute enzyme engineering capacity, GECCO BIOTECH is the profile to seek.
